RhumbLine Advisers’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-275,540
| Closed | -$11.1M | – | 4139 |
|
|
2026
Q1 | $11.1M | Buy |
275,540
+158,623
| +136% | +$3.42M | 0.01% | 1007 |
|
|
2025
Q4 | $2.94M | Sell |
116,917
-512
| -0.4% | -$12K | ﹤0.01% | 1667 |
|
|
2025
Q3 | $2.66M | Sell |
117,429
-4,573
| -4% | -$107K | ﹤0.01% | 1752 |
|
|
2025
Q2 | $2.11M | Sell |
122,002
-2,452
| -2% | -$45.4K | ﹤0.01% | 1855 |
|
|
2025
Q1 | $2.72M | Sell |
124,454
-1,106
| -0.9% | -$30.6K | ﹤0.01% | 1660 |
|
|
2024
Q4 | $4.01M | Sell |
125,560
-295
| -0.2% | -$8.87K | ﹤0.01% | 1534 |
|
|
2024
Q3 | $3.63M | Buy |
125,855
+2,290
| +2% | +$84.8K | ﹤0.01% | 1591 |
|
|
2024
Q2 | $4.74M | Buy |
123,565
+2,644
| +2% | +$120K | ﹤0.01% | 1434 |
|
|
2024
Q1 | $7.11M | Sell |
120,921
-12,665
| -9% | -$807K | 0.01% | 1229 |
|
|
2023
Q4 | $8M | Buy |
133,586
+1,292
| +1% | +$65.5K | 0.01% | 1165 |
|
|
2023
Q3 | $5.03M | Sell |
132,294
-579
| -0.4% | -$25.4K | 0.01% | 1339 |
|
|
2023
Q2 | $12.1M | Buy |
132,873
+1,912
| +1% | +$165K | 0.01% | 925 |
|
|
2023
Q1 | $8.64M | Buy |
130,961
+360
| +0.3% | +$20.8K | 0.01% | 1025 |
|
|
2022
Q4 | $6.75M | Buy |
130,601
+7,412
| +6% | +$393K | 0.01% | 1122 |
|
|
2022
Q3 | $8.41M | Buy |
123,189
+13,256
| +12% | +$784K | 0.01% | 980 |
|
|
2022
Q2 | $4.97M | Buy |
109,933
+32,169
| +41% | +$1.47M | 0.01% | 1246 |
|
|
2022
Q1 | $3.95M | Buy |
77,764
+3,835
| +5% | +$169K | 0.01% | 1455 |
|
|
2021
Q4 | $3.5M | Buy |
73,929
+4,534
| +7% | +$179K | ﹤0.01% | 1576 |
|
|
2021
Q3 | $2.29M | Buy |
69,395
+2,526
| +4% | +$142K | ﹤0.01% | 1830 |
|
|
2021
Q2 | $4.23M | Buy |
66,869
+2,037
| +3% | +$105K | 0.01% | 1512 |
|
|
2021
Q1 | $2.78M | Sell |
64,832
-9,679
| -13% | -$458K | ﹤0.01% | 1747 |
|
|
2020
Q4 | $4.26M | Buy |
74,511
+312
| +0.4% | +$13.2K | 0.01% | 1447 |
|
|
2020
Q3 | $2.24M | Sell |
74,199
-16,237
| -18% | -$485K | ﹤0.01% | 1614 |
|
|
2020
Q2 | $2.95M | Buy |
90,436
+13,003
| +17% | +$418K | ﹤0.01% | 1500 |
|
|
2020
Q1 | $2.07M | Buy |
77,433
+12,185
| +19% | +$433K | ﹤0.01% | 1524 |
|
|
2019
Q4 | $2M | Buy |
65,248
+2,900
| +5% | +$80.3K | ﹤0.01% | 1794 |
|
|
2019
Q3 | $1.5M | Buy |
62,348
+298
| +0.5% | +$8.2K | ﹤0.01% | 1861 |
|
|
2019
Q2 | $1.57M | Buy |
62,050
+15,649
| +34% | +$318K | ﹤0.01% | 1867 |
|
|
2019
Q1 | $905K | Sell |
46,401
-639
| -1% | -$10K | ﹤0.01% | 2089 |
|
|
2018
Q4 | $620K | Buy |
47,040
+15,225
| +48% | +$234K | ﹤0.01% | 2197 |
|
|
2018
Q3 | $566K | Sell |
31,815
-2,137
| -6% | -$39.5K | ﹤0.01% | 2230 |
|
|
2018
Q2 | $747K | Buy |
33,952
+24,645
| +265% | +$566K | ﹤0.01% | 2136 |
|
|
2018
Q1 | $206K | Buy |
+9,307
| New | +$183K | ﹤0.01% | 2590 |
|
Other funds holding APLS
RhumbLine Advisers's APLS Position: Q2 2026 in Review
RhumbLine Advisers sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 275,540 shares — an estimated $11.1M sold.
RhumbLine Advisers first reported a position in APLS in Q1 2018 and held it in 33 quarters. The position peaked at $12.1M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- RhumbLine Advisers reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- RhumbLine Advisers sold 275,540 Apellis Pharmaceuticals shares in Q2 2026, an estimated $11.1M.
- RhumbLine Advisers first reported a position in Apellis Pharmaceuticals in Q1 2018 and held it in 33 quarters.
- RhumbLine Advisers's Apellis Pharmaceuticals position peaked at $12.1M in Q2 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.